The ultrasensitivity of SAGA’s technology creates an array of new possibilities in clinical trials and in the development of new drugs. An example is the ability to find more patients eligible for a specific targeted therapy. When monitoring cancer patients, the technology we present provides crucial quantitative information, leading to breakthrough insights. The methods work equally well with liquid biopsies or tissue biopsies.
The implications of the improved sensitivity/specificity of SAGAsafe® and SAGAsign® are that a new window of possibility is opened to identify the patients carrying ctDNA even between 0.1% to 0.001% mutant allele fraction (MAF).
This results in more efficient trials, increased response and resistance biomarker knowledge, and shorter time from discovery to commercialization of new therapeutics.
Inquire about our services provided in our central laboratory in Lund, or for availability of SAGA kits.
Benefits of the SAGA technology
With SAGA technology, you can be certain you have chosen the best possible tool to assist you in your research and development. With SAGAsafe® and SAGAsign®, you get new information, vital for the results in your clinical studies and for your development of new therapies. Both are ultrasensitive and highly cost-effective methods with a short turn-around time. The possibility to choose between biopsy based on tissue or any suitable body fluid adds flexibility. The stability seen with chromosomal rearrangements, which are used in SAGAsign®, enables long-term use of the same initial fingerprint to monitor clonal evolution throughout a patient’s lifetime.
SAGA is currently involved in a wide range of research-oriented studies in breast cancer, prostate cancer, lung cancer, ovarian cancer, melanoma, colorectal cancer, and AML. We are working with large and small biopharmaceutical companies in both research and clinical trials.
What our customers say
The possibility to choose a liquid biopsy solution for our clinical trial is breaking new ground in the study of colorectal cancer. The SAGAsign® method is well suited for our needs in our current phase II study with Foxy-5.Peter Morsing, CEO of WntResearch